Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): A randomised, double-blind, placebo-controlled phase 3 trial
Daniel P. Petrylak, Nicholas J. Vogelzang, Nikolay Budnik, Pawel Jan Wiechno, Cora N. Sternberg, Kevin Doner, Joaquim Bellmunt, John M. Burke, Maria Ochoa de Olza, Ananya Choudhury, Juergen E. Gschwend, Evgeny Kopyltsov, Aude Flechon, Nicolas Van As, Nadine Houede, Debora Barton, Abderrahim Fandi, Ulf Jungnelius, Shaoyi Li, Ronald de WitKarim Fizazi
Research output: Contribution to journal › Article › peer-review
126Scopus
citations
Fingerprint
Dive into the research topics of 'Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): A randomised, double-blind, placebo-controlled phase 3 trial'. Together they form a unique fingerprint.